PTH and hypoparathyroidism: Other reasons participants in the TransCon PTH group gave for their preference of the trial treatment compared to their previous hypoparathyroidism treatment were experiencing fewer side effects (33.3% n = 5) and improved QOL (26.7%, n = 4):